Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Aficamten in Hypertrophic Cardiomyopathy
2023-508963-58-00Phase 2Authorised
- Sponsor
- Cytokinetics
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, open-label, single-arm trial of aficamten in hypertrophic cardiomyopathy (HCM), sponsored by Cytokinetics. Planned start Jun 2024; status: authorised.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2023-508963-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508963-58-00.